RECURRENT HEPATOCELLULAR CARCINOMA
Clinical trials for RECURRENT HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for tough liver cancers
Disease control OngoingThis early-phase trial tests a new drug combination (IRX-2, cyclophosphamide, and nivolumab) in 8 adults with advanced liver cancer that has returned or spread and no longer responds to standard treatments. The goal is to find the safest dose and check for side effects. The appro…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 07:44 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
Proton beam vs. X-Ray: which radiation is better for liver cancer?
Disease control OngoingThis study compares two radiation therapies for people with liver cancer that cannot be removed by surgery or has come back. One uses standard X-rays (photons), the other uses proton beams that stop after the tumor, possibly causing less harm to healthy tissue. The goal is to see…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control TerminatedThis early-stage trial tests a new treatment for people with advanced liver cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a specific protein called GPC3. The …
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The goal is to find the best dose and see if the combination is safe and can shrink tumors. About 55…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT HEPATOCELLULAR CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC